1 Recent advances in the synthetic and medicinal perspective of quinolones: A review.

2 Chitosan/hydroxyapatite composite bone tissue engineering scaffolds with dual and decoupled therapeutic ion delivery: copper and strontium.

3 Facile preparation of magnetic graphene oxide/nanoscale zerovalent iron adsorbent for magnetic solid-phase extraction of ultra-trace quinolones in milk samples.

4 investigation of plasmid-mediated quinolone resistance in pseudomonas aeruginosa clinical isolates

5 predicting antibiotic resistance, not just for quinolones

6 Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

7 Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones

8 Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

9 Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

10 Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

11 Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones

12 Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

13 Synthesis, in vitro Cytotoxicity and Trypanocidal Evaluation of Novel 1,3,6-Substituted Non-fluoroquinolones

14 Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.

15 Removal of aqueous fluoroquinolones with multi-functional activated carbon (MFAC) derived from recycled long-root Eichhornia crassipes: batch and column studies.

16 Rapid and simultaneous determination of three fluoroquinolones in animal-derived foods using excitation-emission matrix fluorescence coupled with second-order calibration method

17 SYNTHESIS AND ANTIMICROBIAL ACTIVITIES OF NEW 1,2,4- TRIAZOLES, MANNICH BASES, CONAZOLES, AND FLUOROQUINOLONES

18 A new class of dihaloquinolones bearing N'-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-amino ester precursors: synthesis and antimicrobial activity

19 Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities

20 A nanofiber mat prepared from sulfonated polyaniline for solid-phase extraction of fluoroquinolones from water and biological fluids prior to their quantitation by UPLC-MS/MS.

21 Rate constants of hydroxyl radicals reaction with different dissociation species of fluoroquinolones and sulfonamides: Combined experimental and QSAR studies

22 Use of Quinolones for the Treatment of Patients with Bacteremia

23 Long-Term Use of Quinolones and Their Safety

24 New Quinolones: In Vitro Effects as a Potential Source of Clinical Toxicity

25 Use of Quinolones in Chlamydial Infection

26 Susceptibility of Antimicrobial-Resistant Urinary Escherichia coli Isolates to Fluoroquinolones and Nitrofurantoin

27 Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!

28 Pharmacokinetics and Clinical Results of Parenterally Administered New Quinolones in Humans

29 In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli

30 Use of the New Quinolones in Cystic Fibrosis

31 Synergy of Fluoroquinolones with Other Antimicrobial Agents

32 Impact of Fluoroquinolones on the Gastrointestinal Flora

33 Use of Quinolones in Urinary Tract Infections and Prostatitis

34 The New Quinolones: Back to the Future

35 Drug Interactions with Quinolones

36 Results of Treatment with Quinolones of Sexually Transmitted Diseases in the Far East: A Brief Summary

37 Use of Quinolones for the Treatment of Osteomyelitis and Septic Arthritis

38 Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades

39 Quinolones in the Treatment of Lower Respiratory Tract Infections

40 Use of Quinolones in Pediatric Patients

41 Pharmacokinetics of Fluorinated 4-Quinolones in the Aged

42 Use of Quinolones in Chlamydial Infection

43 Prevention of Infections in Granulocytopenic Patients by Fluorinated Quinolones

44 Bacterial Resistance to Quinolones: Mechanisms and Clinical Importance

45 Quinolones in the Treatment of Salmonella Carriers

46 Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network

47 Tissue Penetration of the New Quinolones in Humans

48 Surgical Prophylaxis and Treatment of Surgical Infections with Quinolones

49 Antibiotics in the Management of Shigellosis in Children: What Role for the Quinolones?

50 Post-Marketing Surveillance of the Quinolones: A View from Great Britain

51 Use of Fluoroquinolones for Intracellular Pathogens

52 Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance

53 Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin

54 the inactivation of rnase g reduces the stenotrophomonas maltophilia susceptibility to quinolones by triggering the heat shock response.

55 kinetic spectrophotometric method for the determination of some fourth generation fluoroquinolones in bulk and in pharmaceutical formulations

56 new role of quinolones in respiratory tract infections

57 Synthesis of A-ring quinolones, nine-membered oxolactams and spiroindoles by oxidative transformations of 2,3-indolotriterpenoids.

58 emergence of an extensively drug-resistant salmonella enterica serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins

59 Quinolones in the Treatment of Lower Respiratory Tract Infections

60 Determination of quinolones in environmental water and fish by magnetic metal organic frameworks based magnetic solid-phase extraction followed by high-performance liquid chromatography-tandem mass spectrometry

61 Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB

62 Evaluation of genetic mutations associated with phenotypic resistance to Fluoroquinolones, Bedaquiline, and Linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.

Keyword Connections

Journals

Research Groups

Bibliographies